Investors

Resverlogix through an unrestricted grant, is supporting an educational symposium during the ESC Congress 2019 titled: "Epigenetics: A new pathway to tackle residual risk?"

Saturday, August 31, 2019: 15:30 – 16:30 hrs (Paris, France).

Educational Objectives

• to summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
• to understand the origin of the high residual cardiovascular risk in patients with diabetes and CVD
• to review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
• to update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

Symposium Agenda

Introduction - Ulf Landmesser, MD, Berlin, Germany

Challenges in targeting residual risk in diabetic patients, post ACS - Peter Libby, MD, Boston, USA

BET inhibition, an epigenetic pathway: how could BET inhibition modulate atherothrombotic risk - Wouter Jukema, MD, Leiden, the Netherlands

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition? - Kausik Ray, MD, London, United Kingdom

Video Presentations & Symposium Highlights can be accessed HERE approximately two months following the live event.